Plasma proteomics-based biomarkers for predicting response to mesenchymal stem cell therapy in severe COVID-19
Description
CONCLUSIONS: The responsiveness to MSC therapy appears to depend on baseline level of DDX55, AGRG6, PICAL, CTRB1, and ANXA1. Clinicians should take these factors into consideration when making decision to initiate MSC therapy in patients with severe
